atezolizumab,pembrolizumab,bevacizumab,sunitinib
merck,roche,pfizer
['renal,(-adrenal)', 'atezo', 'pembro']
adjuvant atezolizumab does not show benefit over placebo in high risk renal cancer for dfs/os. no benefit even in m1 subgroup? this contrasts the pembro. immotion150 showed atezo had a rr ~25% in advanced disease. pd-l1 therapy maybe less good than pd1 therapy here. #esmo22 
Interested in Urology Cancers, biomarkers and drug development.